N/A
N=139
Trial of Septra for Uncomplicated Skin Abscesses in Patients at Risk for Community Acquired Methicillin-Resistant Staphylococcus Aureus Infection
Abscess · Methicillin-Resistant Staphylococcus Aureus Infection
Bottom Line
View on ClinicalTrials.gov: NCT00822692 ↗Enrolled (actual)
139
Serious AEs
0.0%
Results posted
Sep 2009
Primary outcome: Primary: Recurrence Rates of Abscesses — 4; 14 participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Trim/ Sulfa DS (Drug); placebo (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- 59th Medical Wing
- Primary completion
- Jun 2009
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Recurrence Rates of Abscesses |
4; 14 | — |
Summary
Patients will be enrolled in a multi-center study (Wilford Hall Medical Center and Brooke Army Medical Center) to prospectively evaluate outcome after treatment for an uncomplicated skin abscess.
Eligibility Criteria
Inclusion Criteria
- All patients age 18-65 who present to the emergency department with a skin abscess that requires incision and drainage.
Exclusion Criteria
- Patients with diabetes, HIV, cancer or other immunocompromised patients.
- Additionally, any patients who received antibiotics within one week of presentation or were hospitalized in previous month will be excluded to minimize potential confounding variables.
- Pregnant and breastfeeding patients will also be excluded due to possible safety concerns with antibiotic treatment.
- Patients with abscesses on head, face, perirectal, or periananal regions, abscesses with known tracks or fistulas to deeper structures, or abscesses requiring surgical drainage in an operating room are excluded.
- Finally, patients with sulfa allergy will be excluded.
Data sourced from ClinicalTrials.gov (NCT00822692). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.